AA
SABS icon

ALPS Advisors’s SAB Biotherapeutics SABS Stock Holding History

ALPS Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303K Buy
+77,600
New +$289K ﹤0.01% 1082
2022
Q2 		– Sell
-4,508
Closed -$170K – 1083
2022
Q1 		$170K Sell
4,508
-523
-10% -$24.1K ﹤0.01% 812
2021
Q4 		$393K Buy
+5,031
New +$472K ﹤0.01% 682

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ALPS Advisors's SABS Position: Q2 2026 in Review

ALPS Advisors opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 77,600 shares worth $303K. The stake represents ﹤0.01% of the portfolio and ranks #1082 among its holdings. This is a return to the name: ALPS Advisors previously reported a position in SABS as recently as Q1 2022.

ALPS Advisors first reported a position in SABS in Q4 2021 and has held it in 3 quarters since. The position peaked at $393K in Q4 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • ALPS Advisors held 77,600 shares of SAB Biotherapeutics worth $303K as of Q2 2026.
  • SAB Biotherapeutics was a new ALPS Advisors position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #1082 holding.
  • ALPS Advisors first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 3 quarters since.
  • ALPS Advisors's SAB Biotherapeutics position peaked at $393K in Q4 2021.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.